Mannkind (MNKD) Notes Payables (2012 - 2025)

Mannkind's (MNKD) quarterly Notes Payables came in at $36.3 million in Q4 2025, little changed on a QoQ basis from $36.2 million in Q3 2025.

Mannkind (MNKD) Notes Payables (2012 - 2025) Analysis & Trends

Mannkind (MNKD) has 8 years of Notes Payables data on file, last reported at $36.3 million in Q4 2025.

On a quarterly basis, Notes Payables changed N/A year-over-year to $36.3 million in Q4 2025; TTM through Dec 2025 was $36.3 million, a N/A change from a year earlier, with the FY2025 full-year figure at $36.3 million, changed N/A from the prior year.
Notes Payables for Q4 2025 stood at $36.3 million, roughly flat from $36.2 million in the prior quarter.
Over the last five years, Notes Payables for MNKD reached as high as $36.3 million in Q4 2025 and fell as low as $36.1 million in Q1 2025.

#	Company	Market Cap	Enterprise Value	Gross Profit (Qtr)
1	Oculis Holding AG	68,785.72 Bn	68,785.72 Bn	-
2	Nanobiotix	1,895.57 Bn	1,895.51 Bn	-
3	BeOne Medicines	471.35 Bn	466.56 Bn	1.35 Bn
4	NuCana	279.75 Bn	279.75 Bn	-
5	Vertex Pharmaceuticals	120.24 Bn	113.00 Bn	2.59 Bn
6	Regeneron Pharmaceuticals	67.80 Bn	59.04 Bn	3.31 Bn
7	Belite Bio	62.51 Bn	62.51 Bn	-
8	Argenx Se	57.38 Bn	57.38 Bn	1.41 Bn
9	Revolution Medicines	37.78 Bn	37.78 Bn	-
10	Mannkind	1.20 Bn	1.07 Bn	82.66 Mn

Download Data